SERA PROGNOSTICS INC-A (SERA) Stock Price, Forecast & Analysis
USA - NASDAQ:SERA - US81749D1072 - Common Stock
SERA Key Statistics, Chart & Performance
The current stock price of SERA is 2.97 USD. In the past month the price decreased by -11.68%. In the past year, price decreased by -51.95%.
SERA Latest News, Press Relases and Analysis
SERA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.73 | 412.77B | ||
| AMGN | AMGEN INC | 15.44 | 181.82B | ||
| GILD | GILEAD SCIENCES INC | 15.28 | 155.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.29 | 112.55B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.47 | 73.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.7 | 60.08B | ||
| INSM | INSMED INC | N/A | 41.44B | ||
| NTRA | NATERA INC | N/A | 27.96B | ||
| BIIB | BIOGEN INC | 10.04 | 24.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.74 | 21.18B | ||
| INCY | INCYTE CORP | 16.52 | 20.71B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.89 | 14.47B |
Related stock screener links
About SERA
Company Profile
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Company Info
SERA PROGNOSTICS INC-A
2749 E. Parleys Way, Suite 200
Salt Lake City UTAH US
CEO: Gregory C. Critchfield
Employees: 63
Phone: 18015050278
SERA PROGNOSTICS INC-A / SERA FAQ
What does SERA do?
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Can you provide the latest stock price for SERA PROGNOSTICS INC-A?
The current stock price of SERA is 2.97 USD. The price increased by 0.68% in the last trading session.
What is the dividend status of SERA PROGNOSTICS INC-A?
SERA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SERA stock?
SERA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SERA PROGNOSTICS INC-A?
SERA PROGNOSTICS INC-A (SERA) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of SERA PROGNOSTICS INC-A (SERA) based on its PE ratio?
SERA PROGNOSTICS INC-A (SERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).
What is SERA PROGNOSTICS INC-A worth?
SERA PROGNOSTICS INC-A (SERA) has a market capitalization of 113.04M USD. This makes SERA a Micro Cap stock.
SERA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SERA. When comparing the yearly performance of all stocks, SERA is a bad performer in the overall market: 78.23% of all stocks are doing better.
SERA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SERA. SERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SERA Financial Highlights
Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 22.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.27% | ||
| ROE | -37.1% | ||
| Debt/Equity | 0 |
SERA Forecast & Estimates
For the next year, analysts expect an EPS growth of 21.7% and a revenue growth 118.18% for SERA